Brianne Jahn
Corporate Officer/Principal bei LIANBIO
Vermögen: 72 354 $ am 31.03.2024
Profil
Brianne Jahn's current job(s) include being the Chief Business Officer at LianBio and a Member-Supervisory Board at Shanghai Lianbio Development Co., Ltd.
Mr. Jahn's former job was as the Senior VP-Finance & Strategic Operations at Kadmon Holdings, Inc. from 2012 to 2020.
Mr. Jahn's education history includes an MBA from New York University and an undergraduate degree from the University of Massachusetts.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
LIANBIO
0,21% | 29.03.2023 | 224 005 ( 0,21% ) | 72 354 $ | 31.03.2024 |
Aktive Positionen von Brianne Jahn
Unternehmen | Position | Beginn |
---|---|---|
LIANBIO | Corporate Officer/Principal | 01.09.2021 |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a private company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Director/Board Member | - |
Ehemalige bekannte Positionen von Brianne Jahn
Unternehmen | Position | Ende |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01.01.2020 |
Ausbildung von Brianne Jahn
New York University | Masters Business Admin |
University of Massachusetts | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
LianBio | |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a private company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |